CA3195597A1

CA3195597A1 - Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders

Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders

Info

Publication number: CA3195597A1
Authority: CA; Canada
Prior art keywords: compound; pharmaceutically acceptable; disease; solvate; metalloenzyme
Prior art date: 2020-10-16
Legal status : Pending

Application number

CA3195597A

Other languages

English (en)

French (fr)

Inventor

Jonnie R. Williams

Current Assignee

Miralogx LLC

Original Assignee

Individual

Priority date

2020-10-16

Filing date

2021-10-16

Publication date

2022-04-21

2021-10-16 Application filed by Individual filed Critical Individual

2022-04-21 Publication of CA3195597A1 publication Critical patent/CA3195597A1/en

Status Pending legal-status Critical Current

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
206010028980 Neoplasm Diseases 0.000 title claims abstract description 12
239000003112 inhibitor Substances 0.000 title abstract description 12
208000024827 Alzheimer disease Diseases 0.000 title abstract description 7
208000018565 Hemochromatosis Diseases 0.000 title abstract description 6
150000001875 compounds Chemical class 0.000 claims abstract description 86
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
208000035475 disorder Diseases 0.000 claims abstract description 14
208000037976 chronic inflammation Diseases 0.000 claims abstract description 6
230000006020 chronic inflammation Effects 0.000 claims abstract description 6
206010006187 Breast cancer Diseases 0.000 claims abstract description 5
208000026310 Breast neoplasm Diseases 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims description 18
239000012453 solvate Substances 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 6
208000024891 symptom Diseases 0.000 claims description 4
230000003110 anti-inflammatory effect Effects 0.000 abstract description 20
102000010750 Metalloproteins Human genes 0.000 abstract description 9
108010063312 Metalloproteins Proteins 0.000 abstract description 9
230000033228 biological regulation Effects 0.000 abstract description 2
208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
230000009286 beneficial effect Effects 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 20
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 20
230000001225 therapeutic effect Effects 0.000 description 20
230000000694 effects Effects 0.000 description 19
239000011701 zinc Substances 0.000 description 19
229910052725 zinc Inorganic materials 0.000 description 16
239000000203 mixture Substances 0.000 description 15
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 14
210000004027 cell Anatomy 0.000 description 14
-1 e.g. Substances 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 14
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
206010061218 Inflammation Diseases 0.000 description 12
230000004054 inflammatory process Effects 0.000 description 12
108091007960 PI3Ks Proteins 0.000 description 11
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 11
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
241000282414 Homo sapiens Species 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
102100040247 Tumor necrosis factor Human genes 0.000 description 9
238000000034 method Methods 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
102000004889 Interleukin-6 Human genes 0.000 description 7
108090001005 Interleukin-6 Proteins 0.000 description 7
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 7
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
108010065805 Interleukin-12 Proteins 0.000 description 6
102000013462 Interleukin-12 Human genes 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000002757 inflammatory effect Effects 0.000 description 6
229940117681 interleukin-12 Drugs 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
150000003180 prostaglandins Chemical class 0.000 description 6
102000013691 Interleukin-17 Human genes 0.000 description 5
108050003558 Interleukin-17 Proteins 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
230000004913 activation Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 5
201000010099 disease Diseases 0.000 description 5
230000006870 function Effects 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
102000003746 Insulin Receptor Human genes 0.000 description 4
108010001127 Insulin Receptor Proteins 0.000 description 4
MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
210000004241 Th2 cell Anatomy 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000001028 anti-proliverative effect Effects 0.000 description 4
239000000090 biomarker Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
230000007838 tissue remodeling Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
101150013553 CD40 gene Proteins 0.000 description 3
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 3
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
108090001007 Interleukin-8 Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
229960001138 acetylsalicylic acid Drugs 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
239000002585 base Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000005094 computer simulation Methods 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000023597 hemostasis Effects 0.000 description 3
230000002519 immonomodulatory effect Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
229960001929 meloxicam Drugs 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
239000006187 pill Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
210000001044 sensory neuron Anatomy 0.000 description 3
230000011664 signaling Effects 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
238000012360 testing method Methods 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 2
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 2
102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
108010083698 Chemokine CCL26 Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
108010037464 Cyclooxygenase 1 Proteins 0.000 description 2
108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
208000001640 Fibromyalgia Diseases 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
DJEIHHYCDCTAAH-UHFFFAOYSA-N Mofezolac (TN) Chemical compound C1=CC(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1 DJEIHHYCDCTAAH-UHFFFAOYSA-N 0.000 description 2
101100239698 Mus musculus Myof gene Proteins 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
239000012828 PI3K inhibitor Substances 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
102000034527 Retinoid X Receptors Human genes 0.000 description 2
108010038912 Retinoid X Receptors Proteins 0.000 description 2
101710190759 Serum amyloid A protein Proteins 0.000 description 2
102100032277 Serum amyloid A-1 protein Human genes 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
208000000491 Tendinopathy Diseases 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
101100239699 Xenopus tropicalis myof gene Proteins 0.000 description 2
229960004420 aceclofenac Drugs 0.000 description 2
229960004892 acemetacin Drugs 0.000 description 2
FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
229950003218 actarit Drugs 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
206010064930 age-related macular degeneration Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960004663 alminoprofen Drugs 0.000 description 2
FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 2
SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 description 2
229950008930 amfenac Drugs 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
229960005430 benoxaprofen Drugs 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229960004830 cetylpyridinium Drugs 0.000 description 2
NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 2
229960001927 cetylpyridinium chloride Drugs 0.000 description 2
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
DGMZLCLHHVYDIS-UHFFFAOYSA-N clometacin Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 2
229950001647 clometacin Drugs 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
201000003146 cystitis Diseases 0.000 description 2
229960002783 dexketoprofen Drugs 0.000 description 2
DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
229960000616 diflunisal Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
229960005293 etodolac Drugs 0.000 description 2
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
229960004945 etoricoxib Drugs 0.000 description 2
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
229960000192 felbinac Drugs 0.000 description 2
ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 2
IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 2
229950006236 fenclofenac Drugs 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
229960002390 flurbiprofen Drugs 0.000 description 2
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
229960003445 idelalisib Drugs 0.000 description 2
YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
229960004187 indoprofen Drugs 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
229960004752 ketorolac Drugs 0.000 description 2
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
229960002373 loxoprofen Drugs 0.000 description 2
YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
229960000994 lumiracoxib Drugs 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
229960003464 mefenamic acid Drugs 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
LMINNBXUMGNKMM-UHFFFAOYSA-N metiazinic acid Chemical compound C1=C(CC(O)=O)C=C2N(C)C3=CC=CC=C3SC2=C1 LMINNBXUMGNKMM-UHFFFAOYSA-N 0.000 description 2
229950005798 metiazinic acid Drugs 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229960000429 mofezolac Drugs 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
229960004270 nabumetone Drugs 0.000 description 2
201000008383 nephritis Diseases 0.000 description 2
239000012454 non-polar solvent Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229960000273 oxametacin Drugs 0.000 description 2
AJRNYCDWNITGHF-UHFFFAOYSA-N oxametacin Chemical compound CC1=C(CC(=O)NO)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AJRNYCDWNITGHF-UHFFFAOYSA-N 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000002304 perfume Substances 0.000 description 2
229960003893 phenacetin Drugs 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
239000003880 polar aprotic solvent Substances 0.000 description 2
229960003101 pranoprofen Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
150000005599 propionic acid derivatives Chemical class 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
229960000371 rofecoxib Drugs 0.000 description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
150000003902 salicylic acid esters Chemical class 0.000 description 2
229960000953 salsalate Drugs 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
229960000894 sulindac Drugs 0.000 description 2
229960004492 suprofen Drugs 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
229960002905 tolfenamic acid Drugs 0.000 description 2
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 2
102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 2
108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 2
229960002004 valdecoxib Drugs 0.000 description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 2
229960003414 zomepirac Drugs 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
OEBJUDGECLJUTH-FQEVSTJZSA-N (3s)-3-[[5-(benzenesulfonamidomethyl)thiophene-2-carbonyl]amino]-5-[(2-chlorophenyl)methylsulfanyl]-4-oxopentanoic acid Chemical compound N([C@@H](CC(=O)O)C(=O)CSCC=1C(=CC=CC=1)Cl)C(=O)C(S1)=CC=C1CNS(=O)(=O)C1=CC=CC=C1 OEBJUDGECLJUTH-FQEVSTJZSA-N 0.000 description 1
JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
108091007505 ADAM17 Proteins 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
206010060937 Amniotic cavity infection Diseases 0.000 description 1
241001550224 Apha Species 0.000 description 1
235000003276 Apios tuberosa Nutrition 0.000 description 1
206010003011 Appendicitis Diseases 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
229940122815 Aromatase inhibitor Drugs 0.000 description 1
CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
206010062746 Carditis Diseases 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
208000008158 Chorioamnionitis Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
206010056340 Diabetic ulcer Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010024212 E-Selectin Proteins 0.000 description 1
102100023471 E-selectin Human genes 0.000 description 1
102100025137 Early activation antigen CD69 Human genes 0.000 description 1
URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000004145 Endometritis Diseases 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
201000011275 Epicondylitis Diseases 0.000 description 1
RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
206010016228 Fasciitis Diseases 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000031448 Genomic Instability Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000005232 Glossitis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
108090000353 Histone deacetylase Proteins 0.000 description 1
102000003964 Histone deacetylase Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
229940124790 IL-6 inhibitor Drugs 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
208000005615 Interstitial Cystitis Diseases 0.000 description 1
102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
108010066327 Keratin-18 Proteins 0.000 description 1
108010070511 Keratin-8 Proteins 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
201000008197 Laryngitis Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000010315 Mastoiditis Diseases 0.000 description 1
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
BRZANEXCSZCZCI-UHFFFAOYSA-N Nifenazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C)C(C)=C1NC(=O)C1=CC=CN=C1 BRZANEXCSZCZCI-UHFFFAOYSA-N 0.000 description 1
JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
101000610236 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) Protein PatA Proteins 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
206010031149 Osteitis Diseases 0.000 description 1
208000002804 Osteochondritis Diseases 0.000 description 1
201000009859 Osteochondrosis Diseases 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
229940124780 PI3K delta inhibitor Drugs 0.000 description 1
229940126033 PPAR agonist Drugs 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
206010034038 Parotitis Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
102100037882 Perilipin-5 Human genes 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010036205 Portal vein phlebitis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
102000015433 Prostaglandin Receptors Human genes 0.000 description 1
108010050183 Prostaglandin Receptors Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
VSQMKHNDXWGCDB-UHFFFAOYSA-N Protizinic acid Chemical compound OC(=O)C(C)C1=CC=C2SC3=CC(OC)=CC=C3N(C)C2=C1 VSQMKHNDXWGCDB-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000004328 Pulpitis Diseases 0.000 description 1
206010037464 Pulpitis dental Diseases 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
208000007893 Salpingitis Diseases 0.000 description 1
206010040628 Sialoadenitis Diseases 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
102400000096 Substance P Human genes 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
208000023835 Tendon disease Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
208000004760 Tenosynovitis Diseases 0.000 description 1
210000000447 Th1 cell Anatomy 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
206010044668 Trigonitis Diseases 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
208000006374 Uterine Cervicitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
206010000496 acne Diseases 0.000 description 1
229940119059 actemra Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000000593 adipose tissue white Anatomy 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229960000212 aminophenazone Drugs 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229960001671 azapropazone Drugs 0.000 description 1
WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
208000002479 balanitis Diseases 0.000 description 1
FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
229960004277 benorilate Drugs 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000333 benzydamine Drugs 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
208000010217 blepharitis Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
208000018339 bone inflammation disease Diseases 0.000 description 1
230000003925 brain function Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
229950003628 buparlisib Drugs 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
UULSXYSSHHRCQK-UHFFFAOYSA-N butibufen Chemical compound CCC(C(O)=O)C1=CC=C(CC(C)C)C=C1 UULSXYSSHHRCQK-UHFFFAOYSA-N 0.000 description 1
229960002973 butibufen Drugs 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
BHRQIJRLOVHRKH-UHFFFAOYSA-L calcium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate;hydron Chemical compound [Ca+2].OC(=O)CN(CC(O)=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O BHRQIJRLOVHRKH-UHFFFAOYSA-L 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000023715 cellular developmental process Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
206010008323 cervicitis Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000009920 chelation Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
229960002688 choline salicylate Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000004927 clay Substances 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000000306 component Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
229940010466 cosentyx Drugs 0.000 description 1
229950006073 cotinine Drugs 0.000 description 1
CIPULDKLIIVIER-VIFPVBQESA-N cotinine N-oxide Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN(=O)=C1 CIPULDKLIIVIER-VIFPVBQESA-N 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
201000004400 dacryoadenitis Diseases 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
MXCPYJZDGPQDRA-UHFFFAOYSA-N dialuminum;2-acetyloxybenzoic acid;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3].CC(=O)OC1=CC=CC=C1C(O)=O MXCPYJZDGPQDRA-UHFFFAOYSA-N 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940120889 dipyrone Drugs 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
229960001850 droxicam Drugs 0.000 description 1
OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
229950010243 emorfazone Drugs 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
208000010227 enterocolitis Diseases 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
229950003801 epirizole Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
OZKQTMYKYQGCME-UHFFFAOYSA-N feclobuzone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1(CCCC)COC(=O)C1=CC=C(Cl)C=C1 OZKQTMYKYQGCME-UHFFFAOYSA-N 0.000 description 1
229950004534 feclobuzone Drugs 0.000 description 1
229960001395 fenbufen Drugs 0.000 description 1
ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960002524 firocoxib Drugs 0.000 description 1
FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 1
229960004369 flufenamic acid Drugs 0.000 description 1
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
229960002258 fulvestrant Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000001280 germinal center Anatomy 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
GWOFUCIGLDBNKM-UHFFFAOYSA-N glafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 GWOFUCIGLDBNKM-UHFFFAOYSA-N 0.000 description 1
229960001650 glafenine Drugs 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
208000002557 hidradenitis Diseases 0.000 description 1
201000007162 hidradenitis suppurativa Diseases 0.000 description 1
210000004295 hippocampal neuron Anatomy 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229940048921 humira Drugs 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
208000009326 ileitis Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
208000021646 inflammation of heart layer Diseases 0.000 description 1
239000003999 initiator Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000000749 insecticidal effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
201000004614 iritis Diseases 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960002202 lornoxicam Drugs 0.000 description 1
OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960003803 meclofenamic acid Drugs 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011785 micronutrient Substances 0.000 description 1
235000013369 micronutrients Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000012184 mineral wax Substances 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
229960005285 mofebutazone Drugs 0.000 description 1
REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229960002187 nifenazone Drugs 0.000 description 1
229960000916 niflumic acid Drugs 0.000 description 1
208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
210000000956 olfactory bulb Anatomy 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
206010030306 omphalitis Diseases 0.000 description 1
208000005963 oophoritis Diseases 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229960002739 oxaprozin Drugs 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
125000005430 oxychloro group Chemical group 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
GHZNWXGYWUBLLI-UHFFFAOYSA-N p-Lactophenetide Chemical compound CCOC1=CC=C(NC(=O)C(C)O)C=C1 GHZNWXGYWUBLLI-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229960004662 parecoxib Drugs 0.000 description 1
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
208000008494 pericarditis Diseases 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
210000002824 peroxisome Anatomy 0.000 description 1
239000003614 peroxisome proliferator Substances 0.000 description 1
239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
239000005426 pharmaceutical component Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229940096826 phenylmercuric acetate Drugs 0.000 description 1
PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
XGNKHIPCARGLGS-UHFFFAOYSA-N pipebuzone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1(CCCC)CN1CCN(C)CC1 XGNKHIPCARGLGS-UHFFFAOYSA-N 0.000 description 1
229950004769 pipebuzone Drugs 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
208000008423 pleurisy Diseases 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000007114 proinflammatory cascade Effects 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
229960002189 propyphenazone Drugs 0.000 description 1
PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
229960002466 proquazone Drugs 0.000 description 1
BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
229950001856 protizinic acid Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
230000006697 redox regulation Effects 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229960000581 salicylamide Drugs 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
208000001076 sarcopenia Diseases 0.000 description 1
229960004540 secukinumab Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
208000001050 sialadenitis Diseases 0.000 description 1
101150015060 sigG gene Proteins 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
229940001474 sodium thiosulfate Drugs 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
208000013515 tendinosis Diseases 0.000 description 1
229960002871 tenoxicam Drugs 0.000 description 1
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
201000005060 thrombophlebitis Diseases 0.000 description 1
HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
229950010302 tiaramide Drugs 0.000 description 1
PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 description 1
229950010298 tinoridine Drugs 0.000 description 1
229960003989 tocilizumab Drugs 0.000 description 1
206010044008 tonsillitis Diseases 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
229910001428 transition metal ion Inorganic materials 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000002003 vulvitis Diseases 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1